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Lactobacillus plantarum CBT LP3
Proinflammatory cytokine
T cell
A B S T R A C T
Lactobacillus plantarum has been identified as a probiotic bacterium owing to its role in immune regulation and
maintenance of intestinal permeability. Here, we investigated the anti-colitic effects and mechanism of L.
plantarum CBT LP3 (LP3). This in vivo study was performed using dextran sodium sulfate (DSS) to induce colitis
in mice. Mice were randomly divided into three groups: a control supplied with normal drinking water, a DSS-
treated group followed by oral administration of vehicle, and a DSS-treated group gavaged with LP3 daily for 7
days following DSS administration. An analysis of macrophages and T cell subsets harvesting from peritonium
cavity cells and splenocytes was performed using a flow cytometric assay. Gene expression and cytokine profiles
were measured using quantitative reverse transcriptase polymerase chain reaction. The administration of LP3
significantly attenuated disease activity and histolopathology compared to control. LP3 had anti-inflammatory
effects, with increased induction of regulatory T cells and type 2 helper T cells in splenocytes and restoration of
goblet cells accompanied by suppression of proinflammatory cytokine expressions. These findings suggest that L.
plantarum CBT LP3 can be used as a potent immunomodulator, which has significant implications for IBD
treatment.
1. Introduction
Inflammatory bowel diseases (IBDs), including ulcerative colitis
(UC) and Crohn’s disease (CD), are chronic relapsing inflammatory
disorders of the gastrointestinal tract (Abraham and Cho, 2009). The
pathogenesis of IBD is still largely unexplained, although it is known
that genetic, environmental, and immunological factors are involved.
Chronic intestinal inflammation in IBD involves an immunologic im-
balance in the macrophages and T cell subsets as well as aberrant in-
flammatory cytokine productions (Fonseca-Camarillo and Yamamoto-
Furusho, 2015). In addition, the intestine’s diverse microbial ecosystem
can affect the differentiation of innate and adaptive immunities by
microbial interaction with the immune system (Hold et al., 2014).
Accumulating evidence indicates that IBDs involve disrupted homeo-
static interactions between the microbiota and the mucosal immune
system, along with subsequent immune dysregulation (Park et al.,
2018; Sartor, 2008).
Despite the various therapeutic options for IBD, current drug-based
treatments have shown limited clinical efficacy and a high incidence of
side effects, including increased infectious complications and drug re-
sistance during treatment (Chande et al., 2015; Lee et al., 2017). Be-
cause of the evidence implicating microbial dysbiosis in IBD, it has been
suggested that probiotics improve dysbiosis and reduce intestinal in-
flammation. Probiotics may be an alternative and safe therapeutic ap-
proach in IBD treatment (Ganji-Arjenaki and Rafieian-Kopaei, 2018).
Probiotics are live microorganisms, which could confer a health benefit
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to the host (Ganji-Arjenaki and Rafieian-Kopaei, 2018). Indeed, recent
studies suggest that probiotics have the ability to ameliorate abnormal
immune responses and have potential benefits in IBD, although con-
flicting results have been observed in clinical use (Dignass et al., 2012;
Ganji-Arjenaki and Rafieian-Kopaei, 2018; Tursi et al., 2010). Probio-
tics can regulate gut barrier function and cytokine production by af-
fecting immune cells such as regulatory T cells, macrophages, and
dendritic cells (Ganji-Arjenaki and Rafieian-Kopaei, 2018). Never-
theless, the mechanisms underlying the effects of most probiotics on
IBD are not well understood.
Lactobacillus plantarum is a lactic acid bacterium found in dairy
products and gastrointestinal, vaginal, and urogenital tracts and used in
the fermentation of dairy products (Seddik et al., 2017). It is known to
inhibit gas-producing bacteria in the intestine and have a positive effect
in some irritable bowel syndrome patients. It is also able to deliver
vehicles for therapeutic compounds or proteins in vivo due to its ability
to survive in the human gastrointestinal tract (Seddik et al., 2017).
Previous studies have shown that L. plantarum has an anti-inflammatory
effect owing to its suppression of proinflammatory cytokines and en-
hancement of the intestinal epithelial barrier (Seddik et al., 2017).
However, despite its safety and promising health benefits, the particular
mechanisms underlying the role of L. plantarum in colitis remain less
understood.
The aim of this study was to explore the role of L. plantarum CBT
LP3 in ameliorating murine colitis and to investigate new options for
IBD treatment. We induced colitis by administration of dextran sulfate
sodium (DSS) in mice to determine the impact of L. plantarum CBT LP3
on gut inflammation and investigate its role in the immune response
and goblet cells.
2. Materials and methods
2.1. Probiotics preparation
Lactobacillus plantarum CBT LP3 (KCTC 10782BP) were kindly pro-
vided by Cell Biotech (Gimpo, Korea). L. plantarum CBT LP3 were cul-
tured in Luria-Bertani broth in a 37 °C incubator and optimally re-
suspended in sterile phosphate-buffered saline (PBS).
2.2. DSS-induced colitis mouse model and assessment
All animals were kept under standard conditions at 21–22 °C under
a 12-h light/dark cycle and were acclimatized for 1 week. Six- or eight-
week-old male C57BL/6 mice (n = 6 / group) were administered
drinking water containing 2.5 % (w/v) DSS (MP Biomedicals, Solon,
OH, USA) for induction of colitis for 7 (day 0–6) or 16 (in survival
experiment) days, and normal, untreated drinking water was adminis-
tered for 9 days as a healing model. Probiotic-treated mice were ad-
ministered 1 × 108 bacteria in 0.1 mL PBS by gavage daily for 7 days
(day 7–15). Peritoneal cavity cells (PCCs), spleen, and colons were
collected. Mice were checked daily for body weight loss, stool con-
sistency, presence of gross blood in the stool or at the anus, and overall
mortality. Disease activity index (DAI), which incorporates body weight
loss, stool consistency, and gross bleeding, was calculated as described
in the previous study (Kim et al., 2019). The entire colon from the
cecum to the anus was removed after sacrificing the mouse and colon
length was measured between the ileocecal junction and the proximal
rectum. The colon was opened and gently cleared of stool using PBS.
The distal colon was cut into 2–3 pieces for periodic acid-Schiff (PAS)
staining and RNA isolation. All animal experiments were performed in
accordance with all applicable Korean laws and were reviewed and
approved by the Institutional Animal Care and Use Committee of Yonsei
University Severance Hospital (IACUC Approval No: 2015-0407).
2.3. Periodic acid-Schiff staining and histomorphological scoring
Colon tissues were fixed with 10 % formalin solution (pH 7.4)
overnight, embedded in paraffin on a slide, and sectioned using stan-
dard protocols. Sections were then deparaffinized and subjected to PAS
staining to evaluate the degree of inflammation. Images were obtained
using a light microscope (Olympus BX41; Olympus Optical, Tokyo,
Japan). The histopathologic evaluation and goblet cell scoring were
evaluated as previously described (Kim et al., 2019).
2.4. Isolation of peritoneal cavity cells from the peritoneum and splenocytes
from the spleen and flow cytometric analysis
PCCs and splenocytes were isolated from peritoneum and spleen of
mice, respectively, as previously described (Seo et al., 2017). After
depletion of red blood cells with RBC lysis buffer, the cells were ana-
lyzed using flow cytometry.
For flow cytometric analysis, single cell suspensions (106 cells) were
blocked with 2.5 % normal mouse and rat serum in FACS buffer (PBS
containing 2 % FBS) and stained for 30 min at 4 °C with the appropriate
antibodies. The antibodies used included: monoclonal anti-Foxp3
(150D/E4), anti-TREM-1 (TR3MBL1), anti-F4/80 (BM8), anti-TLR4
(UT41), and anti-GATA3 (TWAJ) antibodies purchased from
eBioscience (San Diego, CA, USA); monoclonal anti-CD3 (145-2C11)
and anti-CD4 (GK1.5) antibodies purchased from BD Biosciences (San
Jose, CA, USA); and monoclonal anti-CD206 (C068C2) antibody pur-
chased from Biolegend (San Diego, CA, USA). For intracellular staining,
a Foxp3/Transcription factor staining buffer set was purchased from
eBioscience. Data were acquired using a FACSVerse flow cytometer (BD
Biosciences) and analyzed using FlowJo software (Tree Star, San Carlos,
CA, USA).
2.5. Extraction of RNA and quantitative real-time reverse-transcription
polymerase chain reaction
Total RNA was extracted using TRIzol Reagent (Life Technologies,
Carlsbad, CA, USA) and reverse transcribed using a High Capacity
cDNA Reverse Transcription Kit (Thermo Fisher Scientific, Pittsburgh,
PA, USA) according to the manufacturer’s protocol. Amplification was
carried out using SYBR Green Master Mix (Thermo Fisher Scientific) on
a StepOne Plus real-time PCR system (Thermo Fisher Scientific) for 45
cycles using the following thermocycling steps: 95 °C for 30 s, 60–63 °C
for 30 s, and 72 °C for 40 s. All real-time reverse-transcription poly-
merase chain reactions (RT-PCRs) were run in triplicate and quantita-
tive analysis was performed using the relative standard curve method as
described in the previous study (Seo et al., 2017). Results are presented
as fold change compared with the control sample after normalization to
the level of transcription of the endogenous control, β-actin. Real-time
qRT-PCR primers are summarized in Table 1.
Table 1
List of primers used for qRT-PCR.
Gene Sequence (5′‒3′)
Mouse
Tnfa F: CAA AGG GAG AGT GGT CAG GT
R: ATT GCA CCT CAG GGA AGA GT
Il1b F: GCA ACT GTT CCT GAA CTC AAC T
R: ATC TTT TGG GGT CCG TCA ACT
IL10 F: CCC ATT CCT CGT CAC GAT CTC
R: TCA GAC TGG TTT GGG ATA GGT TT
Il17 F: CAG CAG CGA TCA TCC CTC AAA G
R: CAG GAC CAG GAT CTC TTG CTG
Inos F: GGC AGC CTG TGA GAC CTT TG
R: GCA TTG GAA GTG AAG CGT TTC
F: forward primer, R: reverse primer.
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2.6. Statistical analysis
All results were expressed as means of± standard errors of the
means (SEMs). GraphPad Software (La Jolla, CA, USA) was used for all
analysis. The significance of differences between conditions was as-
sessed using Student’s t-test and one-way ANOVA. P values< 0.05 were
considered significant.
3. Results
3.1. Effects of L. Plantarum CBT LP3 on mouse colitis
To induce acute colitis in mice, we administered 2.5 % DSS, which is
widely used in IBD research. The mice then received L. plantarum CBT
LP3 (LP3) or vehicle (PBS) by oral gavage to determine the therapeutic
effects on colitis. DSS treatment induced severe colitis as assessed by
weight loss and DAI scores accompanied by microscopic damage. In
contrast, the LP3-treated group showed a quick recovery from body
weight loss, colon length, and DAI compared to mice in the vehicle-
treated group when DSS was substituted with drinking water
(Fig. 1A–D). Furthermore, the LP3-treated group exhibited a trend of
higher survival compared to the vehicle-treated group with continuing
DSS treatment, although there was no statistical significance (Fig. 2).
Histologic examination consistently revealed an improvement in in-
flammatory signs with reduced inflammatory infiltrates and restored
intestinal epithelia in the LP3-treated group compared to the vehicle-
treated group (Figs. 1D and 3 A), demonstrating that LP3 alleviates
mouse colitis.
3.2. Effects of L. Plantarum CBT LP3 on goblet cell hypoplasia and
proinflammatory cytokine expression in colitis
Goblet cells, known as mucin secretory intestinal epithelial cells
(Kinoshita et al., 2000), are less numerous and more hypotrophic in
DSS-administered colons in mice as well as in intestinal mucosa from
IBD patients compared to healthy intestinal mucosa. To identify the
effects of LP3 on goblet cells, we microscopically assessed goblet cell
loss using PAS-stained colon sections. The vehicle-treated group ex-
hibited severe goblet cell loss, whereas the LP3-treated group showed
significantly increased goblet cells containing high levels of mucus
(Fig. 3A, and B). The proinflammatory cytokines, which play a central
role in the immune response of IBD, are produced by lymphocytes,
monocytes, granulocytes, epithelial cells, and fibroblasts (Fonseca-
Camarillo and Yamamoto-Furusho, 2015). Thus, to assess the expres-
sion levels of proinflammatory cytokines, we performed qRT-PCR for
the major cytokines, such as tumor necrosis factor alpha (Tnfa), inter-
leukin 17 (Il17), and interleukin 1 beta (Il1b), and a mediator of re-
active nitrogen species such as inducible NO synthase (Inos), in the
colon tissues. DSS treatment markedly increased expressions of proin-
flammatory cytokines and Inos compared to the control group, in par-
ticular Il17 and Il1b. In contrast, LP3 treatment significantly suppressed
expression of proinflammatory cytokines and Inos (Fig. 3C).
3.3. Effects of L. Plantarum CBT LP3 on macrophage and T helper cell
polarization
Immune cell responses play a crucial role in the pathogenesis of IBD.
In particular, an imbalance of CD4+ T cells is known to be one of the
major drivers in the disease process. Additionally, M1 macrophages
Fig. 1. Effect of L. plantarum CBT LP3 on DSS-induced mouse
colitis. We administered 2.5 % dextran sodium sulfate (DSS) to
8-week-old male C57BL/6 mice starting from day 0 for 7 days
and changed to pure water for recovery before sacrifice (day
15). The DSS-treated mice were administrated L. plantarum
CBT LP3 (1 × 108) daily by gavage for 7 days (day 7–15).
Body weight (A), colon length (B), disease activity index (C),
and histomorphological score (D) were evaluated.
Data represent mean±SEM (n = 6 / group). ***P<0.005 vs.
Control, #P<0.05 vs. DSS+Veh, ##P<0.01 vs. DSS+Veh.
Control, supplied with normal drinking water; DSS+Veh, DSS-
treated plus PBS; DSS+LP3, DSS-treated plus L. plantarum CBT
LP3.
Fig. 2. Effect of L. plantarum CBT LP3 on the life span of DSS-treated mice. Six-
week-old male C57BL/6 mice were administrated 2.5 % dextran sodium sulfate
(DSS) from day 0 to day 15. The DSS-treated mice were administrated L.
plantarum CBT LP3 (1 × 108) daily by gavage for 7 days (day 0–6). Mouse
mortality was analyzed using Kaplan–Meier plots (n = 6 / group). Survival was
compared using a log-rank test. Control, supplied with normal drinking water;
DSS + Veh, DSS-treated plus PBS; DSS + LP3, DSS-treated plus L. plantarum
CBT LP3.
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Fig. 3. Effect of L. plantarum CBT LP3 on
goblet cell and cytokine expressions in DSS-
treated mice. We administrated 2.5 % dex-
tran sodium sulfate (DSS) to 8-week-old
male C57BL/6 mice from day 0 for 7 days
and changed to pure water before sacrifice
(day 15). The DSS-treated mice were ad-
ministrated L. plantarum CBT LP3 (1 × 108)
daily by gavage for 7 days (day 7–15). (A, B)
Representative images of periodic acid-
Schiff (PAS)-stained goblet cells in the colon
(A) and goblet cell evaluation (B). Scale bar,
20 μm. (C) Transcript level of proin-
flammatory cytokines (Tnfa, Il17, Il1b) and
Inos in the colons. Gene expression analysis
was determined in duplicate using qRT-PCR
analysis.
Data represent mean± SEM (n = 6 /
group). **P<0.01 vs. Control,
***P<0.005 vs. Control, #P<0.05 vs. DSS
+Veh, ##P<0.01 vs. DSS+Veh,
###P<0.005 vs. DSS+Veh. Control, sup-
plied with normal drinking water; DSS
+Veh, DSS-treated plus PBS; DSS+LP3,
DSS-treated plus L. plantarum CBT LP3.
Fig. 4. Effect of L. plantarum CBT LP3 on macrophage and T helper cell subset polarization. (A–C) Flow-cytometric analysis of the Treg (CD4+FOXP3+) and Th2
(GATA3+) populations in the spleens of mice. (A) Representative flow cytometry gating strategies to identify Treg and Th2 populations. (B) Treg cell populations in
splenocytes. (C) Th2 cell populations in splenocytes. (D–G) Flow-cytometric analysis of M1/M2 macrophage populations in peritoneal cavity cells (PCCs) from mice.
(D) Representative flow cytometry gating strategy to identify M1/M2 macrophage populations. (E) CD206+ populations (M2 marker) in PCCs. (F) Mean fluorescence
intensity of TLR4 and TREM-1 (M1 markers) in PCCs.
Data represent mean±SEM (n = 6 / group). *P<0.05 vs. Control, **P<0.01 vs. Control, ***P<0.005 vs. Control, #P<0.05 vs. DSS+Veh. Control, supplied
with normal drinking water; DSS+Veh, DSS-treated plus PBS; DSS+LP3, DSS-treated plus L. plantarum CBT LP3.
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(classically activated macrophages) have a proinflammatory property
and produce high levels of TNF-α, IL-1β, and iNOS, whereas M2 mac-
rophages (alternatively activated macrophages) produce low levels of
proinflammatory cytokines and high levels of IL-10 or TGF-β, resolve
inflammation, and facilitate tissue repair (Benoit et al., 2008). There-
fore, to identify the systemic effects of LP3 on T cell and macrophage
subset responses, we next examined those immune cells from the
peritoneum and spleen of mice using flow cytometry. As shown in
Fig. 4, the LP3-treated group showed drastically increased Treg
(CD4+FOXP3+) and Th2 cell (CD4+GATA3+) populations in the iso-
lated splenocytes compared with those from the vehicle-treated group,
while the DSS-treated group showed significantly reduced Treg and Th2
cell populations. DSS treatment significantly decreased the number of
M2 (CD206+) but increased the number of M1 (TLR4, TREM-1) mac-
rophages in PCCs. However, the number of M2 (CD206+) was only
slightly increased, and the number of M1 (TLR4, TREM-1) macrophages
in LP3-treated mice did not exhibit any significant changes compared
with those from vehicle-treated mice. This finding indicates that LP3
modulates T cells but not macrophages, resulting in protective effects
on colitis, which could explain the decreased Tnfa and Il17 expressions
in the colon.
4. Discussion
Microbial dysbiosis in IBD has been shown to be associated with
increased number of anaerobic bacteria of the genus Bacteroides but
decreased number of the genus Lactobacillus, as well as Bifidobacterium
and Firmicutes, suggesting that an imbalance in intestinal microflora
contributes to IBD pathogenesis (Trier, 2002). Lactobacilli, pre-
dominantly present in the intestine, display a wide range of diversity at
their genetic and physiological levels (Seddik et al., 2017). It has been
reported that Lactobacilli modulate inflammatory cytokine profiles in a
species-dependent manner (Christensen et al., 2002). For example, so-
luble proteins produced by Lactobacillus rhamnosus GG can regulate
intestinal epithelial cell proliferation and prevent cytokine-induced
apoptosis (Yan et al., 2007), although a Lactobacillus rhamnosus GG
clinical trial failed to improve clinical conditions for Crohn’s disease
(CD) (Bousvaros et al., 2005). Lactobacillus casei can induce IL-10 from
macrophages (Shida et al., 2006), and L. paracasei induces an increase
in the population of Treg cells (Seddik et al., 2017) by interaction with
the mucosal immune system. Considering these results, not all probio-
tics are equally beneficial due to different mechanisms of action among
them. Therefore, it is necessary to investigate the mechanisms acting on
different targets in the inflammatory response according to the specific
probiotics.
IBD manifests as mucosal and systemic inflammation occurring
primarily in the intestine, in which goblet cell hypoplasia becomes
prominent. Goblet cells maintain mucous layers and play a critical role
in intestinal barrier function and tissue remodeling (Gordon, 2003; Van
der Sluis et al., 2006). Our knowledge of the beneficial roles of L.
plantarum in gastrointestinal disorders has grown to include the sup-
pression of inflammation and microbial dysbiosis and maintenance of
the intestinal barrier (Seddik et al., 2017). In this study, we provided
new evidence that L. plantarum CBT LP3, a L. plantarum strain, has an
anti-colitic effect. The LP3-treated group improved body weight loss
and shortening of colon length, and DAI as well as histopathology. In-
triguingly, we also found that L. plantarum CBT LP3 effectively restored
goblet cells in the colon.
Increased Th1 and Th17 cells, as well as increased levels of IL-17,
are well-known findings in IBD pathogenesis (Park et al., 2005).
Moreover, defects in Treg cell function and the imbalance of Th cells
resulting in cytokine dysregulation are involved in IBD development
(Fonseca-Camarillo and Yamamoto-Furusho, 2015; Mayne and
Williams, 2013). Probiotics can modulate T cell maturation through
local and systemic interactions with the mucosal immune system
(Ganji-Arjenaki and Rafieian-Kopaei, 2018; Spasova and Surh, 2014).
In our experiment, the DSS-induced colitic mice showed increased ex-
pression of Tnfa (Th1 cytokine) and Il17, whereas LP3-treated mice
displayed decreased Il17 and Tnfa expression in the colon. This eluci-
dates that L. plantarum CBT LP3 inhibits Th17 and Th1 responses in
intestinal inflammation. Furthermore, administration of L. plantarum
CBT LP3 increased Treg and Th2 cell populations in the mouse spleen.
Treg cells, characterized by expression of forkhead transcription factor
Foxp3, are lymphocytes that play a critical role in the pathogenesis of
IBD (Fonseca-Camarillo and Yamamoto-Furusho, 2015). Treg cells
suppress effector T cells and secrete high levels of IL-10 and TGF-―β,
the major anti-inflammatory cytokines in IBD that suppress the pro-
duction of proinflammatory cytokines (Mayne and Williams, 2013; von
der Weid et al., 2001). In addition, Th2 cells, as well as Treg cells, can
change the balance of Th1 and Th17 cells. Furthermore, Th2 and Treg
cells can contribute to goblet cell hyperplasia both in vitro and in vivo
(Liew et al., 2010; Maizels et al., 2009). It was also reported that Th2
cell expansion skews M1 to M2 macrophage phenotype and induces
goblet cell hyperplasia (Liew et al., 2010; Maizels et al., 2009; Miller
et al., 2008; Mohrs et al., 2005; Urban et al., 2007). However, L.
plantarum CBT LP3 did not affect M1 and M2 macrophages in the
peritoneum, suggesting the systemic anti-inflammatory effects and
important immunomodulatory roles occur mainly in lymphocytes. Our
data support, in particular, the notion that gut microbiota can directly
affect T cell maturation (Spasova and Surh, 2014). Given the reduced
Treg cells in IBD patients, the probiotics modulating Treg cells, such as
Bifidobacterium, Streptococcus, and Enterococcus including Lactobacillus,
appear to effectively treat IBD (Konieczna et al., 2012; Kwon et al.,
2010; Roselli et al., 2009; Zhao et al., 2013). L. plantarum CBT LP3 has a
qualified presumption of safety status and is generally recognized as
safe in Europe and North America, and most studies support its safety
(Ganji-Arjenaki and Rafieian-Kopaei, 2018; Seddik et al., 2017). How-
ever, further studies are needed to unravel the exact mechanism un-
derlying the interactions between probiotics and the host immune
system.
5. Conclusion
In conclusion, for the first time, we demonstrated that L. plantarum
CBT LP3 has anti-colitic effects through modulation of T helper cell
subsets and restoration of goblet cells as well as suppression of in-
flammatory cytokines. This regulatory effect of L. plantarum CBT LP3 on
immune modulation holds promise for treatment and prevention of
IBD.
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